newsfilter
← Latest News
GlobeNewswire·

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

– Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary endpoints when